RMD logo

ResMed Inc. Stock Price

NYSE:RMD Community·US$28.1b Market Cap
  • 3 Narratives written by author
  • 1 Comments on narratives written by author
  • 135 Fair Values set on narratives written by author

RMD Share Price Performance

US$192.74
-58.94 (-23.42%)
US$270.60
Fair Value
US$192.74
-58.94 (-23.42%)
28.8% undervalued intrinsic discount
US$270.60
Fair Value
Price US$192.74
AnalystConsensusTarget US$270.60
AnalystLowTarget US$182.45
AnalystHighTarget US$340.00

RMD Community Narratives

·
Fair Value US$270.6 28.8% undervalued intrinsic discount

Analyst Commentary Highlights Margin Optimism as ResMed Faces Market Headwinds and Patent Challenge

2users have liked this narrative
1users have commented on this narrative
61users have followed this narrative
·
Fair Value US$182.45 5.6% overvalued intrinsic discount

GLP 1 Therapies And Margin Pressures Will Challenge Long Term Earnings Sustainability

1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$340 43.3% undervalued intrinsic discount

GLP 1 Therapies And Sleep Apnea Links Will Drive Powerful Long Term Tailwinds

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$270.6
28.8% undervalued intrinsic discount
Revenue
7.67% p.a.
Profit Margin
28.67%
Future PE
23.93x
Price in 2029
US$336.07
US$340
43.3% undervalued intrinsic discount
Revenue
7.99% p.a.
Profit Margin
30.36%
Future PE
28.2x
Price in 2029
US$423.34
US$182.45
5.6% overvalued intrinsic discount
Revenue
6.89% p.a.
Profit Margin
28.02%
Future PE
17.69x
Price in 2029
US$228.72

Trending Discussion

Updated Narratives

RMD logo

RMD: Sleep Health Partnerships And Acquisitions Will Support Long Term Upside

Fair Value: US$270.6 28.8% undervalued intrinsic discount
61 users have set this as their fair value
1 users have commented on this narrative
0 users have liked this narrative
RMD logo

GLP 1 Therapies And Sleep Apnea Links Will Drive Powerful Long Term Tailwinds

Fair Value: US$340 43.3% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
RMD logo

GLP 1 Therapies And Margin Pressures Will Challenge Long Term Earnings Sustainability

Fair Value: US$182.45 5.6% overvalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet, undervalued and pays a dividend.

0 Risks
4 Rewards

ResMed Inc. Key Details

US$5.5b

Revenue

US$2.1b

Cost of Revenue

US$3.4b

Gross Profit

US$1.9b

Other Expenses

US$1.5b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
10.52
62.18%
27.44%
10.2%
View Full Analysis

About RMD

Founded
1989
Employees
10600
CEO
Michael Farrell
WebsiteView website
www.resmed.com

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Recent RMD News & Updates

Seeking Alpha Jun 11

ResMed: GLP-1 Threats Are Overstated

Summary My contrarian take on ResMed is that GLP-1 concerns are overstated, and even though a portion of market share will be lost, the remaining portion will be more beneficial to profitability. Other business threats come from PHG's reentrance and Apnimed's drug commercialization. While not to be overlooked, I still see RMD retaining its market dominance. The stock currently trades as if revenues are already declining and margins are contracting. But the opposite is true. Margins far exceed peers, and the top line grows at double digits. I'm upgrading the stock to a strong buy, as I find the current valuation unjust. Read the full article on Seeking Alpha

Recent updates

No updates